Download PDF

1. Company Snapshot

1.a. Company Description

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection.It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines.


In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases.It serves the life sciences research, clinical diagnostics, and drug discovery applications.Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc.


for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test.The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011.Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Show Full description

1.b. Last Insights on ADPT

Adaptive Biotechnologies Corporation's recent performance was driven by a Q1 earnings beat, with a loss of $0.20 per share versus the estimated loss of $0.28. The company's revenue also topped estimates, with a strong growth trend in its key metrics. Additionally, the consensus price target hints at a 26.5% upside potential, based on Wall Street analysts' expectations. The company's momentum stock status, as identified by analysts, suggests that it has the potential to outperform other medical stocks this year. The company's ability to maintain a strong growth trend, despite a Q1 loss, indicates a positive evolution of business conditions.

1.c. Company Highlights

2. Adaptive Biotechnologies Beats Earnings Estimates with Strong Revenue Growth

Adaptive Biotechnologies reported a strong fourth quarter with total company revenue reaching $71.7 million, representing a 63% year-over-year growth. The MRD business was the main driver, with revenue growing 54% year-over-year to $61.9 million. The company's adjusted EBITDA was $4.1 million, a significant improvement from the loss of $16.4 million in the same quarter last year. The actual EPS was $-0.09, beating estimates of $-0.19. Analysts estimate revenue growth at 22.7% for next year.

Publication Date: Feb -24

📋 Highlights

MRD Business Continues to Drive Growth

The MRD business continued to be the growth engine for Adaptive Biotechnologies, with clonoSEQ clinical testing revenue growing 64% for full-year 2025 and 59% in the fourth quarter. The company achieved a record 30,038 tests in the fourth quarter, up 43% year-over-year and 11% sequentially. The growth was broad-based across all reimbursed indications, with DLBCL, MCL, and multi-myeloma driving the majority of the year-over-year growth.

Guidance and Outlook

The company provided guidance for 2026, expecting full-year revenue for the MRD business to be between $255 million and $265 million. The company also expects to exit Q4 with positive EBITDA. As Chad Robins mentioned, "our focus this year is clear: continuing to drive top-line growth while expanding margins, building on the same durable growth drivers that powered performance in 2025."

Valuation Metrics

Looking at the valuation metrics, the company's P/S Ratio is 8.48, and EV/EBITDA is -68.7. The ROE is -30.0%, and ROIC is -13.09%. These metrics indicate that the market is pricing in significant growth expectations, but the company's current financial performance is still in the red. The Net Debt / EBITDA ratio is -5.64, indicating a healthy cash position.

Competitive Landscape

The company is confident in its competitive position, with Susan Bobulsky stating that "flow-based methods for MRDs are inherently less sensitive than clonoSEQ." The company is also investing in making its data more accessible to pharma clients, with revenue from the IM business offsetting the net burn.

3. NewsRoom

Card image cap

Allianz Asset Management GmbH Raises Stock Holdings in Adaptive Biotechnologies Corporation $ADPT

Feb -11

Source: defenseworld.net

Card image cap

Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript

Feb -06

Source: seekingalpha.com

Card image cap

Chad Robins Sells 124,998 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Feb -06

Source: defenseworld.net

Card image cap

Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Feb -06

Source: zacks.com

Card image cap

Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates

Feb -05

Source: zacks.com

Card image cap

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

Feb -05

Source: globenewswire.com

Card image cap

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Jan -27

Source: globenewswire.com

Card image cap

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

Jan -22

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.64%)

6. Segments

Minimal Residual Disease - Service

Expected Growth: 12%

Adaptive Biotechnologies' Minimal Residual Disease (MRD) service growth is driven by increasing adoption in blood cancer diagnosis and monitoring, expanding test menu, and growing demand for personalized medicine. Additionally, partnerships with pharmaceutical companies and increasing awareness of MRD's clinical utility contribute to the 12% growth rate.

Immune Medicine - Collaboration

Expected Growth: 10%

Immune Medicine's 10% growth is driven by Adaptive Biotechnologies Corporation's collaboration, leveraging its proprietary immune profiling technology to identify novel therapeutic targets. This partnership accelerates drug discovery, enhances pipeline development, and expands market reach, ultimately driving revenue growth.

Immune Medicine - Service

Expected Growth: 13%

Adaptive Biotechnologies Corporation's Immune Medicine service growth is driven by increasing demand for personalized medicine, advancements in immunotherapy, and rising incidence of diseases such as cancer and autoimmune disorders. Additionally, the company's proprietary immune profiling technology and partnerships with pharmaceutical companies contribute to its 13% growth.

7. Detailed Products

clonoSEQ

A diagnostic test that detects and monitors minimal residual disease (MRD) in patients with certain blood cancers, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and multiple myeloma.

immunoSEQ

A platform that uses next-generation sequencing (NGS) to analyze the immune system's T-cell and B-cell receptors, providing insights into the immune response.

Mindera

A software platform that integrates with immunoSEQ to provide a comprehensive view of the immune system, enabling researchers to analyze and visualize immune response data.

LymphoSIGHT

A research-use-only test that analyzes the immune system's T-cell and B-cell receptors to understand the immune response to cancer and infectious diseases.

8. Adaptive Biotechnologies Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Adaptive Biotechnologies Corporation is moderate, as there are alternative technologies and products available in the market, but the company's unique sequencing-based approach provides a competitive advantage.

Bargaining Power Of Customers

The bargaining power of customers is low, as Adaptive Biotechnologies Corporation's products and services are highly specialized and there are limited alternative options available, giving the company significant pricing power.

Bargaining Power Of Suppliers

The bargaining power of suppliers is moderate, as Adaptive Biotechnologies Corporation relies on a few key suppliers for critical components, but the company's strong relationships and diversified supply chain mitigate the risk of supplier concentration.

Threat Of New Entrants

The threat of new entrants is high, as the biotechnology industry is rapidly evolving and new companies are emerging with innovative technologies, posing a significant threat to Adaptive Biotechnologies Corporation's market share.

Intensity Of Rivalry

The intensity of rivalry is high, as Adaptive Biotechnologies Corporation operates in a highly competitive industry with several established players, and the company must continually innovate and differentiate its products and services to maintain its market position.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 31.23%
Debt Cost 6.02%
Equity Weight 68.77%
Equity Cost 10.29%
WACC 8.96%
Leverage 45.41%

11. Quality Control: Adaptive Biotechnologies Corporation passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Phathom Pharmaceuticals

A-Score: 4.9/10

Value: 8.2

Growth: 4.6

Quality: 5.8

Yield: 0.0

Momentum: 10.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Fortress Biotech

A-Score: 4.7/10

Value: 7.7

Growth: 5.3

Quality: 6.1

Yield: 0.0

Momentum: 7.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
AnaptysBio

A-Score: 4.5/10

Value: 8.2

Growth: 3.2

Quality: 3.8

Yield: 0.0

Momentum: 10.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Adaptive Biotechnologies

A-Score: 4.3/10

Value: 6.0

Growth: 3.8

Quality: 4.7

Yield: 0.0

Momentum: 9.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
REGENXBIO

A-Score: 3.8/10

Value: 6.8

Growth: 2.2

Quality: 4.5

Yield: 0.0

Momentum: 7.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Tonix Pharmaceuticals

A-Score: 3.7/10

Value: 7.8

Growth: 5.3

Quality: 3.8

Yield: 0.0

Momentum: 5.0

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

16.08$

Current Price

16.08$

Potential

-0.00%

Expected Cash-Flows